Known as amyloid-related imaging abnormalities ... has no symptoms and often goes away on its own, it can cause brain ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

The drug was found to trigger amyloid-related imaging abnormalities ... Of the patients who took the drug, 31 per cent were found to have brain bleeds. For those taking the placebo, the risk ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Although amyloid-beta is present in healthy brains, in people with Alzheimer’s, it clumps together to form plaques, which interfere with the normal workings of the brain. This, scientists ...

Known as amyloid-related imaging abnormalities ... has no symptoms and often goes away on its own, it can cause brain swelling, bleeding, as well as headaches and confusion.

Intracerebral hemorrhage is a medical emergency (Broderick et al., 1999). Initial diagnosis is achieved by using an emergent brain computed ... past hemorrhages, amyloid angiopathy, and neoplasm ...

For more than three decades, scientists have been racing to stop Alzheimer's disease by removing amyloid beta plaques - sticky clumps of toxic protein that accumulate in the brain. Now ...

Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain.

The EMA has rejected the Alzheimer’s disease therapy Kisunla (donanemab) from Eli Lilly and Co., saying the benefits of the anti-amyloid antibody do not outweigh the risks of edema and hemorrhage in ...